A lifestyle intervention or metformin prevented or delayed the onset of type 2 diabetes in people at risk
QUESTION: In overweight people with elevated fasting and postload plasma glucose concentrations, does a lifestyle intervention or treatment with metformin prevent or delay the onset of type 2 diabetes mellitus?
Randomised (allocation concealed), blinded (clinicians and participants for metformin and placebo), placebo controlled trial with a mean follow up of 2.8 years (range 1.8–4.6 y).
27 centres in the US.
3234 participants ≥25 years of age (mean age 51 y, 68% women) without diabetes who had a body mass index ≥24 kg/m2 (≥22 kg/m2 for Asians), plasma glucose concentration of 5.3–6.9 mmol/l in the fasting state and 7.8–11.0 mmol/l 2 hours after a 75 g oral glucose load. Exclusion criteria included taking medicines known to alter glucose tolerance and illnesses that could seriously reduce life expectancy or ability to participate in the trial. Follow up was 93%.
Participants were allocated to an intensive programme of lifestyle modification (n=1079) or standard lifestyle …